Paul Tudor Jones Evolus, Inc. Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$7.15 - $10.2 $588,738 - $839,878	-82,341 Reduced 59.18%	56,802 $519,000
Q2 2023 Aug 14, 2023	BUY	$7.23 - $10.52 $244,757 - $356,133	33,853 Added 32.15%	139,143 $1.01 Million
Q1 2023 May 15, 2023	BUY	$7.81 - $11.05 $18,697 - $26,453	2,394 Added 2.33%	105,290 $891,000
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.95 $136,281 - $187,072	20,902 Added 25.49%	102,896 $773,000
Q3 2022 Nov 14, 2022	BUY	$7.76 - $13.72 $396,931 - $701,791	51,151 Added 165.84%	81,994 $660,000
Q2 2022 Aug 15, 2022	BUY	$10.22 - $13.94 $315,215 - $429,951	30,843 New	30,843 $358,000
Q1 2020 May 15, 2020	SELL	$3.53 - $12.21 $122,833 - $424,871	-34,797 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.58 - $17.37 $402,949 - $604,423	34,797 New	34,797 $423,000

168

47.8M

130K

51K

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $608M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.